Sustainability and Corporate Social Responsibility
Annual Reports on Corporate Social Responsibility Policy
Compliance Policy
Since it was founded in 2000, Oryzon Genomics S.A. has grown in a responsible, prudent manner, with an efficient management of its resources and with a clear commitment to research and development. We work to develop new epigenetics-based therapeutics with the aim to improve human health, focusing on therapeutic areas with unmet medical needs.
We strive to develop our activities committed to the highest standards of business ethics and with the unalterable willingness to comply with all applicable legislation.
The Board of Directors and the management team of Oryzon Genomics S.A. are firmly committed to continuing to develop and raise awareness among the employees on matters related to the compliance with the law and with the company values.
As part of the company’s compliance program, Oryzon’s Board of Directors approved on 29th July 2019 the Compliance Model and the Code of Ethics and Conduct that shall be binding to everyone working at Oryzon Genomics S.A.
Policy regarding communication and contacts with shareholders, institutional investors and proxy advisors
The policy regarding communication and contacts with shareholders, institutional investors and proxy advisors, approved by the Board of Directors, aims to generate confidence in the Company’s national and foreign shareholders and investors and to promote transparency in the information that the Company makes public.
Code of Ethics and Conduct
The purpose of Oryzon’s Code of Ethics and Conduct, approved by the Board of Directors on 29th July 2006, is to formalize the Company’s commitment to the principles of business ethics and transparency in all our areas of action, establishing a set of principles and guidelines aimed at guaranteeing the ethical and responsible behavior of all of the persons concerned in the performance of their duties.
